Article Text

Download PDFPDF
Letter
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation
  1. Célia Gouynou1,
  2. Lieven Pouillon1,2,
  3. Hélène Rousseau3,
  4. Camille Zallot1,
  5. Cédric Baumann3,
  6. Laurent Peyrin-Biroulet1
  1. 1 Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France
  2. 2 Imelda GI Clinical Research Centre, Imeldaziekenhuis Bonheiden, Bonheiden, Belgium
  3. 3 Clinical Research Support Facility PARC, UMDS Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France
  1. Correspondence to Prof Laurent Peyrin-Biroulet, Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Lorraine 54 511, France; peyrinbiroulet{at}gmail.com

Statistics from Altmetric.com

We read with interest the recent paper by Colombel et al 1 showing that vedolizumab is frequently used for patients with inflammatory bowel disease (IBD). There is evidence for an exposure–efficacy relationship for vedolizumab induction therapy.2 Increasing dosing frequency of vedolizumab to every 4 weeks leads to an improvement in clinical response in both ulcerative colitis (UC)3 and Crohn’s disease (CD).4 In contrast to anti-tumour necrosis factor (TNF) agents, the correlation between the response to dose optimisation and changes in the pharmacokinetic profile of vedolizumab-treated patients remains unknown. We performed a retrospective analysis of all vedolizumab-treated …

View Full Text

Footnotes

  • CG and LP contributed equally.

  • Contributors CG and LP collected data, interpreted data and drafted the manuscript. HR and CB performed statistical analysis, interpreted data and critically revised the manuscript. CZ collected data and critically revised the manuscript. LP-B designed the study, interpreted data and critically revised the manuscript.

  • Competing interests CG, LP, HR, CZ and CB have nothing to disclose. LP-B received consulting fees from Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillotts, Vifor, Pharmacosmos, BMS, UCB-Pharma, Hospira, Celltrion, Takeda, Biogaran, Boehringer-Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera and Samsung Bioepis and received lecture fees from Merck, AbbVie, Takeda, Janssen, Ferring, Norgine, Tillotts, Vifor, Mitsubishi and HAC-Pharma.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Data sharing statement There are no additional unpublished data from the study available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Inflammatory bowel disease
    Jean-Frédéric Colombel Bruce E Sands Paul Rutgeerts William Sandborn Silvio Danese Geert D'Haens Remo Panaccione Edward V Loftus, Jr Serap Sankoh Irving Fox Asit Parikh Catherine Milch Brihad Abhyankar Brian G Feagan